Annual Review of Psychology
August 2, 2024
Keith Humphreys, Daniel Stjepanović, Wayne Hall et al.
18 citations
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...
Pharmacological Reports
August 1, 2024
Maja Owe-Larsson, Katarzyna Kamińska, Barbara Buchalska et al.
11 citations
Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early...
Current Psychopharmacologye
July 4, 2024
Hussein El Bourji, Aziz Farhat, Zahi Hamdan et al.
Background: Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest emerged in its use for substance use disorders. Methods: In this review of the literature, we summarize available trials looking at the use of psilocybin in addiction Results: One double-blind, randomized clinical trial looked at the effect of...
Psychoactives
July 3, 2024
Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al.
4 citations
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....
Cannabis and Cannabinoid Research
June 17, 2024
Madeline K Stanger, Harmony O Soffer, Angela D Bryan et al.
1 citation
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from a larger observational study on...
Frontiers in Psychiatry
June 11, 2024
Sandra Szafoni, Piotr Gręblowski, Klaudia Grabowska et al.
12 citations
Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conducted to find effective alternatives to traditional therapies. One of these alternatives is psilocybin, a psychedelic substance that has been tested in clinical trials as an adjunct to psychotherapy. These studies focus on patients with major...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
June 10, 2024
Linda Nguyen, Sona Regonda, Adam Gaisinsky
Introduction: Psilocybin is a naturally occurring tryptamine derivative psychedelic compound potently produced by fungi members of the genus Psilocybe. Previous literature has highlighted psilocybin as a serotonin 2A receptor agonist with striking effects on neural plasticity and cognition. Recent studies explore the usage of psilocybin in addressing addictive behaviours and substance abuse....
Psychopharmacology
May 14, 2024
Mazen A Atiq, Matthew R Baker, Jennifer L. Vande Voort et al.
12 citations
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the...
May 2, 2024
Hanna Brancaccio
Introduction: Substance use disorder (SUD) and alcohol use disorder (AUD) are major public health crises, affecting millions of Americans. Current treatment options include behavioral therapies and medications. In this review, we explored psilocybin’s efficacy in treating SUD and AUD. Methods: Key terms were used to search databases to identify articles that addressed psilocybin in the...
Neurology
April 9, 2024
Tina Singh, Dipa Patel, Kasey Bishop et al.
1 citation
To uncover the underlying mechanisms between the usage of psilocybin and its impact on the rehabilitation from substance use disorders (SUD).